The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pincus, S. H.
Right arrow Articles by Gorse, G. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pincus, S. H.
Right arrow Articles by Gorse, G. J.

The Journal of Immunology, Vol 158, Issue 7 3511-3520, Copyright © 1997 by American Association of Immunologists

ARTICLES

Vaccine-specific antibody responses induced by HIV-1 envelope subunit vaccines

SH Pincus, KG Messer, R Cole, R Ireland, TC VanCott, A Pinter, DH Schwartz, BS Graham and GJ Gorse
Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, Hamilton, MT 59840, USA. spincus@montana.edu

The first generation of candidate vaccines to prevent HIV infection consisted of recombinant envelope proteins (Env, gp120, and gp160) derived from a single laboratory strain of HIV, designated IIIB/LAV, but produced with different expression systems. In this study we examined the fine specificity of the human Ab response to each vaccine and compared them to the responses of laboratory workers infected with the same strain of HIV. The best responders from each vaccine protocol were studied and compared. Detailed comparisons of the fine specificity of the Ab response were possible because all immunologic assays were performed using homologous recombinant proteins, peptides, and virus stocks. Although the total amounts of anti-Env Ab were comparable, the groups exhibited significant differences in epitope specificity, avidity, and functional capacity of the Ab response. The data demonstrate that the form of the immunogen (e.g., live virus or recombinant protein) is important in determining the quality of the Ab response. Conclusions are also drawn regarding characteristics of the anti-HIV-neutralizing Ab response. These studies represent one of the most detailed analyses of the human Ab response to any Ag and have implications for the development of vaccines for HIV as well as for other microbial pathogens.


This article has been cited by other articles:


Home page
 J. Virol.Home page
H. E. Neuman de Vegvar, R. R. Amara, L. Steinman, P. J. Utz, H. L. Robinson, and W. H. Robinson
Microarray Profiling of Antibody Responses against Simian-Human Immunodeficiency Virus: Postchallenge Convergence of Reactivities Independent of Host Histocompatibility Type and Vaccine Regimen
J. Virol., October 15, 2003; 77(20): 11125 - 11138.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
J. F. L. Richmond, S. Lu, J. C. Santoro, J. Weng, S.-L. Hu, D. C. Montefiori, and H. L. Robinson
Studies of the Neutralizing Activity and Avidity of Anti-Human Immunodeficiency Virus Type 1 Env Antibody Elicited by DNA Priming and Protein Boosting
J. Virol., November 1, 1998; 72(11): 9092 - 9100.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1997 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1997 by The American Association of Immunologists, Inc. All rights reserved.